Prevalence and impact of germline mutations in pancreatic ductal adenocarcinoma

Research Article

Germline pathogenic variants are increasingly recognized as critical determinants of pancreatic ductal adenocarcinoma (PDAC) susceptibility, prognosis, and response to targeted therapies such as PARP inhibitors. Recent guidelines recommend germline testing for all PDAC patients, regardless of family history, to identify hereditary cancer syndromes and guide treatment decisions. However, data from populations underrepresented in genomic studies, such as the Turkish population, remain limited.

Expectant management or conization for persistent low-grade cervical intraepithelial neoplasia: Analysis of 5-year outcomes

Research Article

To investigate to describe outcomes of conization or expectant management for women with persistent (>24 months) low-grade cervical intra-epithelial neoplasia.
This is a retrospective analysis focusing on five-year outcomes after persistent, histologically confirmed, low-grade cervical intra-epithelial neoplasia undergoing conization or expectant management.

Volunteering in a pediatric oncology unit: Motivations and duration

Research Article

Volunteers play an essential role in pediatric oncology. While they are driven by personal motivations, they usually receive specific training that may support or reshape their goals.
We conducted a questionnaire-based survey to assess demographics, motivations, and satisfaction among eight associations/non-profit organizations, representing approximately 120 volunteers. The objectives were to explore the nature and correlations of their motivations to evaluate the sustainability of their engagement.

Trends in histological subtypes of cutaneous melanoma in the Netherlands from 1989 to 2023 – Influence of sunlight exposure and overdiagnosis

Research Article

Melanoma incidence has continued to increase over the past decades with unchanged mortality. Different sunshine exposures across the generations complicate the interpretation of the trends. It is further suggested that half of the rising incidence rate is caused by overdiagnosis. We compared the time trends in the major but not all sunlight-related histological subtypes of cutaneous melanoma in the Netherlands in 1989-2023.

Nutritional status as a risk factor for adverse events associated with L-Asparaginase in children with acute lymphoblastic leukemia

Research Article

Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, and asparaginase (ASNase) is a key component of its treatment. However, ASNase is frequently associated with adverse events (AEs), such as pancreatitis and hypersensitivity reactions particularly with the Escherichia coli derived formulation (L-Asp) which may be influenced by nutritional status.

Synergistic effects of XPO1 inhibitors combined with CD19 CAR-T cells in TP53-mutated DLBCL

Research Article

Diffuse large B-cell lymphoma (DLBCL) is mostly curable by chemotherapy, but p53 mutations limit the therapeutic effect of DLBCL. Although chimeric antigen receptor (CAR) T cells have made revolutionary progress in the treatment of DLBCL, p53 mutations still lead to drug resistance and/or relapse of DLBCL, affecting the prognosis of lymphoma. Therefore, the project aims to explore additional therapeutic strategies to improve the prognosis of DLBCL with p53 mutations.

LDCT-based lung cancer screening and small cell lung cancer: Limited but non-negligible impact on survival. A brief report

Research Article

Low-dose computed tomography (LDCT)-based lung cancer screening (LCS) seems to have very limited impact on small cell lung cancer (SCLC) outcomes. This study aims at describing frequency and outcomes of SCLC in a large LCS population.
Patients diagnosed with SCLC among the total population enrolled in three different trials (n = 7473) were selected for the present analysis.

From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switching

Research Article

Patients with HER2+ breast cancer (BC) can receive pertuzumab/trastuzumab (PT) subcutaneous (SC) or intravenous (IV) with similar efficacy. This study explores patients and healthcare professionals (HCPs) perceptions post-PT-SC implementation, alongside a pharmacoeconomic analysis.
This multicentre observational study included semi-structured interviews with HER2+ BC patients (SC or IV) and HCPs from six Lombardy (Italy) BC units plus a pharmacoeconomic analysis of organisational and cost impact. Data were analysed using descriptive statistics and thematic analysis to identify key themes: safety perception, treatment comfort, and trust issues.